BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+ in Prostate Cancer

BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+ in Prostate Cancer

  • US$2,054,651 non-dilutive grant from the US National Cancer Institute to complete manufacturing of Bria-Pros+ TM clinical supply and support Phase 1/2a trial in metastatic prostate cancer
  • Expands Bria-OTS+ novel personalized off-the-shelf immunotherapy platform to prostate cancer, an urgent unmet medical need
  • Principal Investigator: Dr. William Oh, MD, Yale Cancer Center

briacell therapeutics corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) (" BriaCell " or the " Company "), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that the National Cancer Institute (NCI), the United States federal government's principal agency for cancer research and training, has awarded the Company a research grant of $2,054,651 to advance Bria-PROS+, BriaCell's next generation personalized off-the-shelf immunotherapy for prostate cancer.

The non-dilutive grant, titled "Phase 1/2a clinical trial to investigate Bria-PROS+™ in patients with metastatic prostate cancer", will be used to complete manufacturing of Bria-PROS+ and to fund the upcoming Phase 1/2a study in patients with advanced prostate cancer.

"Despite recent advances in the management of metastatic hormone-sensitive prostate cancer, most patients will progress with significant pain and suffering and limited treatment options," stated Dr. William Oh, MD, Director of Precision Medicine, Yale Cancer Center, and Principal Investigator on the upcoming Phase 1/2a clinical study of Bria-PROS+ in advanced prostate cancer. "We are grateful to the NCI for recognizing the urgency for this unmet medical need and supporting BriaCell's breakthrough immunotherapy."

"This prestigious award will help expedite the clinical development of Bria-PROS+ and is significant validation of our next generation novel personalized immunotherapy approach," added Dr. William V. Williams, BriaCell's President and CEO.

"The Bria-OTS+ platform was designed to overcome the complexity, cost and delays of traditional personalized cancer treatments," noted Miguel Lopez-Lago, PhD, BriaCell's Chief Scientific Officer. "We believe it will constitute a significant advancement in personalized cancer care."

About briacell therapeutics corp.

BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/ .

Safe Harbor

This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include statements regarding the completion of manufacturing of Bria-PROS+; the outcome of the Phase 1/2a clinical trial in metastatic breast cancer; and the ongoing development of Bria-PROS+. These statements are based on BriaCell's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading "Risks and Uncertainties" in the Company's most recent Management's Discussion and Analysis, under the heading "Risk Factors" in the Company's most recent Annual Information Form and under "Risks and Uncertainties" in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company's profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov . Forward-looking statements contained in this announcement are made as of this date and briacell therapeutics corp. undertakes no duty to update such information except as required under applicable law.

Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

Company Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com

Investor Relations Contact:
investors@briacell.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

BCT:CA
The Conversation (0)
TSX:BCT

BriaCell

Developing Personalized Off-The-Shelf Immunotherapy Treatments for Cancer Patients

Developing Personalized Off-The-Shelf Immunotherapy Treatments for Cancer Patients Keep Reading...
BriaCell Partners with New York Cancer & Blood Specialists  for Pivotal Phase 3 Study of Bria-IMT in Advanced Breast Cancer

BriaCell Partners with New York Cancer & Blood Specialists for Pivotal Phase 3 Study of Bria-IMT in Advanced Breast Cancer

briacell therapeutics corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce a partnership with New York Cancer & Blood Specialists (NYCBS), a group of... Keep Reading...
BriaCell Initiates Pivotal Phase 3 Study of Bria-IMT in Advanced Metastatic Breast Cancer

BriaCell Initiates Pivotal Phase 3 Study of Bria-IMT in Advanced Metastatic Breast Cancer

The randomized pivotal Phase 3 study is expected to enroll a total of 354 patients in either Bria-IMT™ combination or physician's choice therapy (1:1) Positive results of the pivotal Phase 3 study could result in full approval and marketing authorization for Bria-IMT™ The study's primary... Keep Reading...
BriaCell Reports Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer

BriaCell Reports Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer

Median overall survival of 13.5 months in BriaCell's advanced metastatic breast cancer patients (vs. 6.7-9.8 months for similar patients reported in the literature) 21 out of 29 patients treated since 2022 are still alive suggesting a strong survival benefit for BriaCell's combination regimen No... Keep Reading...
BriaCell Therapeutics Corp. Announces Closing of Plan of Arrangement Spinning Out BriaPro Therapeutics Corp. to Existing Shareholders

BriaCell Therapeutics Corp. Announces Closing of Plan of Arrangement Spinning Out BriaPro Therapeutics Corp. to Existing Shareholders

briacell therapeutics corp. closes Arrangement effecting the distribution described in the plan of arrangement. briacell therapeutics corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (" BriaCell " or the " Company "), a clinical-stage biotechnology company that develops novel immunotherapies to transform... Keep Reading...
BriaCell Accepts Letter of Intent from Weill Cornell Medicine Outlining Plans to Initiate a Clinical Trial of Bria-IMT in High-Risk Early-Stage Triple Negative Breast Cancer

BriaCell Accepts Letter of Intent from Weill Cornell Medicine Outlining Plans to Initiate a Clinical Trial of Bria-IMT in High-Risk Early-Stage Triple Negative Breast Cancer

briacell therapeutics corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that it has accepted a letter of intent from Dr. Massimo Cristofanilli, Director of Breast... Keep Reading...
Biotech therapy capsule containing DNA strand surrounded by cells.

Top 4 Canadian Biotech Stocks of 2025

Biotech is a dynamic industry that is driving scientific advances and innovation in healthcare. In Canada, the biotech sector is home to companies pursuing cutting-edge therapies and medical technologies.Here the Investing News Network profiles the five best-performing Canadian biotech stocks on... Keep Reading...
Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into Q3 2027

Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into Q3 2027

MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRx™ in recurrent pericarditis is fully funded through to a planned New Drug Application submission with the FDA.New data from the ARCHER trial, highlighting the magnitude of reduction in left ventricular (LV) mass and the read... Keep Reading...
Funded Collaboration Agreement with Protect Animal Health

Funded Collaboration Agreement with Protect Animal Health

Invion Limited (IVX:AU) has announced Funded Collaboration Agreement with Protect Animal HealthDownload the PDF here. Keep Reading...
Canadian Investment Regulatory Organization Trade Resumption - CRDL

Canadian Investment Regulatory Organization Trade Resumption - CRDL

Trading resumes in: Company: Cardiol Therapeutics Inc. TSX Symbol: CRDL All Issues: Yes Resumption (ET): 8:00 AM CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly... Keep Reading...
Cardiol Therapeutics Secures US$11 Million Financing and Extends Cash Runway into Q3 2027

Cardiol Therapeutics Secures US$11 Million Financing and Extends Cash Runway into Q3 2027

MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRx™ in recurrent pericarditis is fully funded through to a planned New Drug Application submission with the FDA.New data from the ARCHER trial, highlighting the magnitude of reduction in left ventricular (LV) mass and the read... Keep Reading...
Repayment of Lind Facility with Successful Capital Raise

Repayment of Lind Facility with Successful Capital Raise

Invion Limited (IVX:AU) has announced Repayment of Lind Facility with Successful Capital RaiseDownload the PDF here. Keep Reading...

Latest Press Releases

Related News